Trial ID or NCT#

NCT02267603

Status

NOT RECRUITING

Purpose

This phase II trial studies how well pembrolizumab works in treating patients with Merkel cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to other parts of the body. Pembrolizumab may stimulate the immune system to identify and destroy cancer cells.

Official Title

A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Hans-Christoph Becker
Radiologist
Professor of Radiology (General Radiology) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Sunil Reddy
(650) 736-1234